Follicum AB

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Follicum AB - overview

Established

2004

Location

Lund, -, Sweden

Primary Industry

Biotechnology

About

Follicum AB is a biotechnology company focused on developing innovative treatments for hair loss, leveraging proprietary peptides to stimulate hair follicle activity and promote hair regeneration. Founded in 2004 and headquartered in Lund, Sweden, Follicum AB develops therapeutic solutions for hair loss. The company has engaged in three total funding deals, with the most recent occurring on August 29, 2018, when it raised DKK 1 million in a GRANT from the Novo Nordisk Foundation. To date, Follicum has raised a total of DKK 0.


50 mn. The company was founded without reference to a parent company or notable mergers. Follicum specializes in the development of treatments for hair loss, focusing on innovative peptides designed to stimulate hair follicle activity and enhance hair regeneration. These products target biological pathways relevant to conditions like androgenetic alopecia, serving both consumers dealing with hair loss and healthcare providers seeking effective treatments in dermatology and trichology.


The company’s solutions are distributed in various regions, including Europe and North America. Follicum generates revenue through direct-to-consumer sales and partnerships with healthcare providers and distributors. The transaction structure focuses on relationships with clinics and dermatologists, who recommend Follicum's peptide products to patients experiencing hair loss. The revenue comes from these signature products, which are offered via subscription plans or one-time purchases, facilitating consistent user engagement while ensuring steady revenue flow.


Specific pricing details are proprietary, reflecting Follicum's positioning in the hair care market. Follicum AB aims to expand its product line and enter new markets. The most recent funding round on August 29, 2018, involved DKK 1 million, part of a larger DKK 1. 40 million grant, which is intended to support further product development and market expansion initiatives.


Target markets for growth include increasing presence in North America and enhancing product offerings within Europe.


Current Investors

Heartcore Capital, Novo Nordisk Foundation

Primary Industry

Biotechnology

Sub Industries

Biotechnology, Healthcare

Website

www.follicum.com

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Follicum AB - financials

Fiscal Year EndedDec 31, 2011Dec 31, 2012Dec 31, 2013Dec 31, 2014Dec 31, 2015Dec 31, 2016Dec 31, 2017Dec 31, 2018Dec 31, 2019Dec 31, 2020
Revenue (USD)----------
% Revenue Growth (YoY)----------
EBITDA (USD)(614,164)(1,868,557)(5,239,338)(6,227,763)(19,087,924)(20,560,779)(17,449,503)---
Operating Income (USD)(614,164)(1,868,557)(5,239,338)(6,227,763)(19,087,924)(20,560,779)(17,563,553)---
Operating Margin----------
% EBITDA Margin----------
NET Income (USD)(607,575)(1,848,044)(5,185,603)(6,183,181)(19,021,471)(20,536,742)(17,519,556)---
% Net Margin----------

Follicum AB - employee data

Blurred Background

Want to see Employee Count?

Request a demo for full access to this profile.

Follicum AB - key contacts

NamePositionStart DateEnd DateVcardBio 
Board MemberBM
Member of the BoardBM
Chairman of the board/board member from Oct. 1 2015BM

BM Board Member

Want to see more?

Request a demo for full access to this profile

GoingPro

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.